398 related articles for article (PubMed ID: 30961933)
21. Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.
Boulet LP; Abbott C; Brusselle G; Edwards D; Oppenheimer J; Pavord ID; Pizzichini E; Sagara H; Slade D; Wechsler ME; Gibson PG
J Allergy Clin Immunol Pract; 2024 May; 12(5):1244-1253.e8. PubMed ID: 38309696
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
[TBL] [Abstract][Full Text] [Related]
23. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
McKeage K
Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
[TBL] [Abstract][Full Text] [Related]
24. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
Feldman WB; Avorn J; Kesselheim AS; Gagne JJ
JAMA Intern Med; 2023 Jul; 183(7):685-695. PubMed ID: 37213116
[TBL] [Abstract][Full Text] [Related]
25. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Bollmeier SG; Prosser TR
Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
[TBL] [Abstract][Full Text] [Related]
26. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
27. The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease.
Bakerly ND; Browning D; Boucot I; Crawford J; McCorkindale S; Stein N; New JP
Ther Adv Respir Dis; 2021; 15():17534666211001013. PubMed ID: 33781142
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Ismaila AS; Risebrough N; Schroeder M; Shah D; Martin A; Goodall EC; Ndirangu K; Criner G; Dransfield M; Halpin DM; Han MK; Lomas DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2681-2695. PubMed ID: 31819401
[TBL] [Abstract][Full Text] [Related]
29. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
32. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
33. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma.
Rogliani P; Matera MG; Cazzola M
Drugs Today (Barc); 2015 Aug; 51(8):469-78. PubMed ID: 26380385
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease.
Siederer S; Allen A; Yang S
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):743-758. PubMed ID: 26474864
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
[TBL] [Abstract][Full Text] [Related]
36. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
Adachi M; Goldfrad C; Jacques L; Nishimura Y
Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
[TBL] [Abstract][Full Text] [Related]
38. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
39. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA; Barnacle H; Birk R; Brealey N; Locantore N; Lomas DA; Ludwig-Sengpiel A; Mohindra R; Tabberer M; Zhu CQ; Pascoe SJ
Am J Respir Crit Care Med; 2017 Aug; 196(4):438-446. PubMed ID: 28375647
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
